Ikaria Holdings said it has acquired the new drug application and the investigational new drug application for Lucassin from Orphan Therapeutics.

Through the acquisition, Ikaria assumes future development and ownership of the drug in Australia and North America.

The drug is being developed for the treatment of hepatorenal syndrome (HRS) Type 1, an orphan-designated condition.

HRS Type 1 is characterised by kidney failure in patients with late-stage liver cirrhosis and onset of renal failure with a high mortality rate exceeding 80% within three months.

Lucassin is a synthetic vasopressin analogue, which mainly acts as a systemic vasoconstrictor in the abdominal circulation, improving renal function in patients with HRS.